Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis

Alessandro Mantovani, Giorgia Beatrice, Andrea Dalbeni – 4 April 2020 – At present, there is scarce information regarding the global prevalence of chronic liver disease in individuals with coronavirus disease 2019 (COVID‐19) disease, which is becoming a global pandemic. The aim of this study was to assess the overall prevalence of chronic liver disease among patients with COVID‐19 disease by meta‐analysing data in observational studies and to investigate the relationship between liver damage and COVID‐19 disease.

Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

Stephane Daffis, Scott Balsitis, Jason Chamberlain, Jim Zheng, Rex Santos, William Rowe, Dhivya Ramakrishnan, Divya Pattabiraman, Sandra Spurlock, Ruth Chu, Don Kang, Michael Mish, Ricardo Ramirez, Li Li, Bei Li, Sarina Ma, Magdeleine Hung, Christian Voitenleitner, Changsuek Yon, Manasa Suresh, Stephan Menne, Paul Cote, William E. Delaney, Richard Mackman, Simon P. Fletcher – 4 April 2020

Bile Composition as a Diagnostic and Prognostic Tool in Liver Transplantation

Isabel M. A. Brüggenwirth, Robert J. Porte, Paulo N. Martins – 4 April 2020 – Bile secretion and composition reflects the functional status of hepatocytes and cholangiocytes. Bile composition can have a role in the assessment of donor grafts before implantation in the recipient. In addition, changes in bile composition after liver transplantation can serve as a diagnostic and prognostic tool to predict posttransplant complications, such as primary nonfunction, acute cellular rejection, or nonanastomotic biliary strictures.

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

James M. Paik, Pegah Golabi, Rakesh Biswas, Saleh Alqahtani, Chapy Venkatesan, Zobair M. Younossi – 4 April 2020 – In the United States, chronic viral hepatitis B and C (CHB and CHC), nonalcoholic fatty liver disease (NAFLD), and alcohol‐related liver disease (ALD) are the main causes of liver deaths attributable to hepatocellular carcinoma (HCC) and cirrhosis. Our aim was to assess the changes in the rates of mortality and years of potential life lost (YLL) for HCC and cirrhosis due to different liver diseases.

Subscribe to